Carroll Investors’s Pfizer PFE Stock Holding History

Carroll Investors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,736	Closed	-$288K	–	29
2023 Q3	$288K	Buy	+8,736	New	+$309K	0.26%	20
2022 Q3	–	Sell	-7,712	Closed	-$404K	–	47
2022 Q2	$404K	Hold	7,712	–	–	0.37%	22
2022 Q1	$397K	Hold	7,712	–	–	0.25%	23
2021 Q4	$452K	Buy	+7,712	New	+$382K	0.26%	24

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Carroll Investors's PFE Position: Q4 2023 in Review

Carroll Investors sold out of Pfizer (PFE) in Q4 2023, closing a stake of 8,736 shares — an estimated $288K sold.

Carroll Investors first reported a position in PFE in Q4 2021 and held it in 4 quarters. The position peaked at $452K in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

Carroll Investors reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
Carroll Investors sold 8,736 Pfizer shares in Q4 2023, an estimated $288K.
Carroll Investors first reported a position in Pfizer in Q4 2021 and held it in 4 quarters.
Carroll Investors's Pfizer position peaked at $452K in Q4 2021.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on Carroll Investors's 13F filing for Q4 2023, filed 14 Feb 2024.